Compositions and methods of treating subjects with brca1 mutation or deficiency

Abstract

The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., carries a BRCA1 mutation). The present disclosure also …